18 December 2023 - Catalyst Pharmaceuticals today announced that its collaboration partner, DyDo Pharma reported that it has submitted a new ...
12 December 2023 - Submission supported by positive results of a Phase 3 study showing immune response and safety in adults ...
6 December 2023 - BMS announced today that the company has received manufacturing and marketing approval of the supplemental new ...
27 November 2023 - Exclusive Partner in Japan, Meiji Seika Pharma advances regulatory approval. ...
28 November 2023 - - Daiichi Sankyo today announced that Daichirona for intramuscular injection (DS-5670) for booster vaccination has been ...
24 November 2023 - Ono Pharmaceutical today announced that ONO has received supplemental approval of Opdivo (nivolumab) intravenous infusion, a ...
26 September 2023 - Celltrion said it has received marketing approval from the Japanese Ministry of Health, Labor, and Welfare ...
25 September 2023 - Approval triggers $1.5 million milestone payment to Cara. ...
25 September 2023 - Approval is based on clinical studies conducted in Japan, Europe and North America confirming the ffficacy and ...
25 September 2023 - Eisai and Biogen announced today that humanised anti-soluble aggregated amyloid-beta monoclonal antibody “Leqembi intravenous infusion” (200 mg, ...
25 September 2023 - Approvals are based on pivotal phase 3 data for both medicines, showing statistical and clinically relevant improvements ...
7 September 2023 - – Daiichi Sankyo today announced that it has submitted a supplemental New Drug Application to Japan’s ...
24 August 2023 - Soliris reduced disease severity and symptoms with sustained improvements over 26 weeks in Phase III clinical ...
23 August 2023 - Approval based on DESTINY-Lung02 results showing Enhertu demonstrated a clinically meaningful tumour response of 53.8% in ...
26 June 2023 - Shingrix (recombinant zoster vaccine) is already approved in Japan for adults aged 50 and over. ...